KYMR ▼ -0.6% - Kymera Therapeutics, Inc. $KYMR - Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses Kymera Therapeutics shares fell 0.6% today following the company's announcement of presentations on KT-621, its oral STAT6 degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology congresses. The presentations showcase the drug candidate across respiratory and dermatological indications, though the modest decline suggests investors may be awaiting more substantial clinical data or efficacy readouts. 01-SEP-2026 07:01 AM ET